Solventum (NYSE:SOLV) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Solventum (NYSE:SOLV) from a buy rating to a hold rating in a research report released on Sunday morning.

A number of other research firms have also commented on SOLV. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Stifel Nicolaus increased their target price on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. UBS Group reiterated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.70.

Solventum Price Performance

SOLV stock opened at $69.30 on Friday. Solventum has a one year low of $60.70 and a one year high of $88.20. The firm has a 50-day moving average of $77.62 and a two-hundred day moving average of $76.20. The firm has a market capitalization of $12.02 billion, a PE ratio of 7.81, a P/E/G ratio of 1.14 and a beta of 0.40. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. During the same period last year, the firm posted $1.41 earnings per share. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Solventum declared that its Board of Directors has approved a share buyback plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 7.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Solventum

Institutional investors have recently modified their holdings of the stock. Hilltop National Bank increased its stake in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares during the last quarter. CrossGen Wealth LLC acquired a new stake in Solventum during the fourth quarter valued at $25,000. Measured Wealth Private Client Group LLC purchased a new position in Solventum in the third quarter valued at about $25,000. Deseret Mutual Benefit Administrators grew its stake in Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after purchasing an additional 163 shares in the last quarter. Finally, JNBA Financial Advisors increased its position in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after purchasing an additional 228 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.